NASDAQ:ANDS - Anadys Pharmaceuticals Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
Previous CloseN/A
Today's RangeN/A
52-Week RangeN/A
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A

About Anadys Pharmaceuticals (NASDAQ:ANDS)

Anadys Pharmaceuticals, Inc. is a biopharmaceutical company engaged in developing medicines for the treatment of hepatitis C. The Company is focusing on the development of ANA598, a direct-acting antiviral (DAA) for the treatment of hepatitis C. It also focuses to resume the clinical development of ANA773, an oral, small-molecule inducer of endogenous interferons that acts via the Toll-like receptor 7, or TLR7, pathway for the treatment of hepatitis C. In January 2011, the Company initiated a Phase IIb clinical study of ANA598 in combination with SOC for the treatment of hepatitis C. In the Phase IIb study, approximately 200 chronically infected genotype 1 hepatitis C patients are to receive ANA598 200 mg bid in combination with standard of care (SOC), with a loading dose of 800 mg ANA598 bid on day one. In addition, approximately 66 chronically infected genotype 1 hepatitis C patients are to receive placebo added to SOC.

Receive ANDS News and Ratings via Email

Sign-up to receive the latest news and ratings for ANDS and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry N/A


Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A


Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A


EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A


Outstanding SharesN/A

Anadys Pharmaceuticals (NASDAQ:ANDS) Frequently Asked Questions

What is Anadys Pharmaceuticals' stock symbol?

Anadys Pharmaceuticals trades on the NASDAQ under the ticker symbol "ANDS."

Has Anadys Pharmaceuticals been receiving favorable news coverage?

Media stories about ANDS stock have been trending somewhat positive on Sunday, Accern reports. The research group identifies negative and positive press coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Anadys Pharmaceuticals earned a daily sentiment score of 0.24 on Accern's scale. They also assigned media stories about the biopharmaceutical company an impact score of 47.10 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the near future.

How do I buy shares of Anadys Pharmaceuticals?

Shares of ANDS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How can I contact Anadys Pharmaceuticals?

Anadys Pharmaceuticals' mailing address is Suite 200, 5871 Oberlin Drive, SAN DIEGO, CA 92121, United States. The biopharmaceutical company can be reached via phone at +1-858-5303600.

MarketBeat Community Rating for Anadys Pharmaceuticals (ANDS)

Community Ranking:  2.1 out of 5 (star star)
Outperform Votes:  50 (Vote Outperform)
Underperform Votes:  70 (Vote Underperform)
Total Votes:  120
MarketBeat's community ratings are surveys of what our community members think about Anadys Pharmaceuticals and other stocks. Vote "Outperform" if you believe ANDS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ANDS will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Anadys Pharmaceuticals (NASDAQ:ANDS) Analyst Ratings History

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
(Data available from 5/27/2016 forward)


Anadys Pharmaceuticals (NASDAQ:ANDS) Earnings History and Estimates Chart

Earnings by Quarter for Anadys Pharmaceuticals (NASDAQ:ANDS)

Anadys Pharmaceuticals (NASDAQ ANDS) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/7/2011($0.14)($0.15)ViewN/AView Earnings Details
8/8/2011($0.12)($0.14)ViewN/AView Earnings Details
5/5/2011($0.10)($0.10)ViewN/AView Earnings Details
3/3/2011($0.09)($0.04)ViewN/AView Earnings Details
11/8/2010Q3 2010($0.10)($0.11)ViewN/AView Earnings Details
7/29/2010Q2 2010($0.14)($0.08)ViewN/AView Earnings Details
4/27/2010Q1 2010($0.17)($0.17)ViewN/AView Earnings Details
2/24/2010Q4 2009($0.17)($0.15)ViewN/AView Earnings Details
10/29/2009Q3 2009($0.20)($0.21)ViewN/AView Earnings Details
7/30/2009Q2 2009($0.27)($0.21)ViewN/AView Earnings Details
4/23/2009Q1 2009($0.30)($0.30)ViewN/AView Earnings Details
2/26/2009Q4 2008($0.33)($0.30)ViewN/AView Earnings Details
10/23/2008Q3 2008($0.26)($0.32)ViewN/AView Earnings Details
7/30/2008Q2 2008($0.28)($0.25)ViewN/AView Earnings Details
4/30/2008Q1 2008($0.26)($0.26)ViewN/AView Earnings Details
2/20/2008Q4 2007($0.28)($0.27)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)


Anadys Pharmaceuticals (NASDAQ:ANDS) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Anadys Pharmaceuticals (NASDAQ ANDS) Insider Trading and Institutional Ownership History

Insider Trading History for Anadys Pharmaceuticals (NASDAQ:ANDS)

Anadys Pharmaceuticals (NASDAQ ANDS) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
(Data available from 1/1/2013 forward)


Anadys Pharmaceuticals (NASDAQ ANDS) News Headlines

No headlines for this company have been tracked by

SEC Filings

Anadys Pharmaceuticals (NASDAQ:ANDS) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media


Anadys Pharmaceuticals (NASDAQ:ANDS) Income Statement, Balance Sheet and Cash Flow Statement


Anadys Pharmaceuticals (NASDAQ ANDS) Stock Chart for Sunday, May, 27, 2018

Loading chart…

This page was last updated on 5/27/2018 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.